FLI-1在非小細胞肺癌之表現及意義

Friend氏白血病融合蛋白-1（FLI-1），是一種針對C-末端FLI-1蛋白結合結構區域的抗體，已被用來作為在小藍色圓形細胞和血管腫瘤的鑑別診斷的有用工具，但是在少數報告肺癌腫瘤細胞的表現卻不一致。本研究的目的是評估FLI-1在非小細胞肺癌（NSCLC）的免疫組織化學染色表現，及其臨床病理參數及預後之間的關係。研究方法使用108例非小細胞肺癌的多個腫瘤基因芯片研究其FLI-1蛋白的免疫組織化學表現。在FLI-1的表現與臨床病理參數和預後的意義之間的相關性進行了分析。使用Kaplan-Meier生存分析和Cox比例風險模型來分析FLI-1表現對整體存活的影響。我們的研究結果顯示FLI-1蛋白表現高比FLI-1蛋白表現低的非小細胞肺癌患者有統計學上顯著意義較短的整體存活（OS; P = 0.01）。多變量分析則顯示，高FLI-1蛋白的表現被確認是非小細胞肺癌的獨立預後不良因素（整體存活-危險比（HR），7.292；95％可信賴區間（CI），0.294-0.823；P=0.007）。研究結論，FLI-1在不同種類的非小細胞肺癌中表現不同，其高度表現與較差預後有關；然而，仍需要進一步的研究來闡明其在非小細胞肺癌腫瘤發生所扮演的功能及角色。

關鍵字

非小細胞肺癌； FLI-1

並列摘要

Friend leukemia integration-1 (FLI-1) antibody, a commercially available antibody directed against the C-terminus of FLI-1 protein-binding domain, has been used as a useful tool in the differential diagnosis of small blue round cell tumors and vascular neoplasms, but shows inconsistent expression in lung cancers. The aims of this study were to evaluate FLI-1 immunohistochemical expression in non-small cell lung carcinomas (NSCLC), and its relationships between the clinicopathological parameters and prognosis. We investigated the FLI-1 expression in 108 cases of NSCLC by using multiple tumor microarrays. Correlations between the FLI-1 expression and clinicopathological parameters and prognostic significance were analyzed. The effect of FLI-1 expression on survival is estimated by Kaplan–Meier survival analysis and Cox proportional hazards models. Our results revealed patients with high FLI-1 expression had shorter overall survival (OS; P=0.01) than those with low FLI-1 expression. In multivariate analysis, FLI-1 was confirmed as an independent poor prognostic factor in NSCLC (OS-hazard ratio (HR), 7.292; 95 % confidence interval (CI), 0.294-0.823; P=0.007). In conclusion, this study shows that FLI-1 is expressed variably in different subtypes of NSCLC, and its expression is related to poorer prognosis. However, further studies are required to elucidate its function in tumorigenesis of NSCLC.